Sorry, you need to enable JavaScript to visit this website.
This promotional website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the UK.
Report adverse events

Prescribing information, details of adverse event reporting and indications can be found at the bottom of this page.

With BIKTARVY® data, you and your patient can feel confident today, tomorrow, and for the days to come1–5

Biktarvy campaign - prescribe with confidence

Prescribe with confidence

Robust* and durable efficacy through 5 years in treatment naïve, and 2 years in virologically suppressed participants with 0 treatment-emergent resistance† in pivotal‡ trials.1–5

Find out more
Biktarvy Campaign - take with ease

Take with ease

Easy to manage regimen‖1

Find out more
Biktarvy campaign - long term health

Focus on long-term health

Well-tolerated with 2% discontinuations due to AEs in pivotal‡ randomised clinical trials§1–7

Find out more

Abbreviations:

3TC, lamivudine; ABC, abacavir; AE, adverse event; ATV, atazanavir; DRV, darunavir; DTG, dolutegravir; FTC, emtricitabine; M=E, missing=excluded; M=F, missing=failure; OLE, open-label extension; RCTs, randomised controlled trials; SmPC, Summary of Product Characteristics; STR, single-tablet regimen; TAF, tenofovir alafenamide; VL, viral load.

References:

  1. BIKTARVY® Summary of Product Characteristics. 
  2. Sax P, et al. eClinicalMedicine. 2023;59:101991. 
  3. Brar I, et al. Infectious Diseases (ID) Week 2020, 21–25 October. Poster 1028. 
  4. Rockstroh JK, et al. HIV Glasgow 2020, 5–8 October; Glasgow, UK. Poster 036. 
  5. Orkin C, et al. HIV Glasgow 2022, 23–28 October; Glasgow, UK. Poster P088.  
  6. Molina JM, et al. Lancet HIV. 2018;5(7):e357–e365.  
  7. Daar ES et al. Lancet HIV. 2018;5(7):e347–e356.  
  8. US Department of Health and Human Sciences (DHHS). What to Start: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, March 2023. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf. Accessed February 2026.
  9. Cihlar T, et al. Curr Opin Virol. 2016;18:50–56.
  10. Trottier B, et al. J Int AIDS Soc. 2014;17(Suppl 3):19765.
  11. Orkin C, et al. HIV Med. 2018;19:18–32.
  12. Orkin C, et al. Lancet HIV. 2020;7(6):e389–e400.
  13. Gallant J, et al. Lancet 2017;390:2063–2072.
  14. Sax PE, et al. Lancet 2017;390:2073–2082.

UK-BVY-0703 Date of preparation February 2026